scholarly journals Lower Brain-Derived Neurotrophic Factor in Patients with Prader-Willi Syndrome Compared to Obese and Lean Control Subjects

2010 ◽  
Vol 31 (3) ◽  
pp. 398-398
Author(s):  
Joan C. Han ◽  
Michael J. Muehlbauer ◽  
Huaxia N. Cui ◽  
Christopher B. Newgard ◽  
Andrea M. Haqq
Keyword(s):  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Peripheral Circulation ◽  
Cross Sectional Study ◽  
Analysis Of Covariance ◽  
Cross Sectional ◽  
Clinical Research Center ◽  
Melanocortin Signaling ◽  
Serum Bdnf

ABSTRACT Context Brain-derived neurotrophic factor (BDNF) haploinsufficiency is associated with hyperphagia and obesity in both animals and humans. BDNF appears to function downstream of the leptin-melanocortin signaling pathway to control energy balance. The potential role of BDNF in the etiology of the severe hyperphagia associated with PWS has not been previously explored. Objective The aim was to compare BDNF concentrations in subjects with PWS and obese controls (OC) and lean controls (LC). Design and Setting We conducted a cross-sectional study at an outpatient clinical research center. Participants We studied 13 subjects with PWS [five males and eight females; mean ± sd: age, 11.0 ± 4.1 yr; body mass index (BMI)-Z, 2.05 ± 0.78], 13 OC (eight females, five males; age, 12.3 ± 2.7 yr; BMI-Z, 2.18 ± 0.61), and 13 LC (six females, seven males; age, 12.4 ± 2.6 yr; BMI-Z, −0.57 ± 0.73). Main Outcome Measure BDNF was measured in serum and plasma by ELISA. Analysis of covariance adjusted for age, sex, and BMI-Z. Results All groups were comparable for age (P = 0.50) and sex distribution (P = 0.49). BMI-Z was comparable between PWS and OC (P = 0.89) and lower in LC (P < 0.001). Adjusted serum BDNF was comparable (P = 0.35) in OC (mean ± sem: 13.5 ± 1.2 ng/ml) and LC (19.2 ± 1.3 ng/ml), but lower in PWS (8.3 ± 1.2 ng/ml; P = 0.01 vs. OC; P = 0.03 vs. LC). Adjusted plasma BDNF in PWS (217 ± 130 pg/ml) was lower than OC (422 ± 126 pg/ml; P = 0.02), but statistically comparable with LC (540 ± 143 pg/ml; P = 0.10). Conclusions Lower BDNF in PWS suggests insufficient central BDNF production because BDNF in peripheral circulation is believed to reflect cerebral BDNF output. Decreased BDNF may be a potential cause for the disordered satiety and morbid obesity associated with PWS. Further studies are needed to confirm this preliminary pilot study in a larger cohort of patients with PWS.

scholarly journals Epigenetic perspective on the role of brain-derived neurotrophic factor in burnout

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Jelena Bakusic ◽  
Manosij Ghosh ◽  
Andrea Polli ◽  
Bram Bekaert ◽  
Wilmar Schaufeli ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Depressive Symptoms ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Cross Sectional Study ◽  
Sample Collection ◽  
Cross Sectional ◽  
Val66met Polymorphism ◽  
Significant Difference

Abstract Brain-derived neurotrophic factor (BDNF) plays a potential role in the neurobiology of burnout, but there are no studies investigating the underlying genetic and epigenetic mechanisms. Our aim is to further explore the role of BDNF in burnout, by focusing on the Val66Met polymorphism and methylation patterns of the BDNF gene and serum BDNF (sBDNF) protein expression. We conducted a cross-sectional study by recruiting 129 individuals (59 with burnout and 70 healthy controls). Participants underwent a clinical interview, psychological assessment and blood sample collection. Polymorphism and DNA methylation were measured on DNA from whole blood, using pyrosequencing and sBDNF levels were measured using ELISA. We found significantly increased methylation of promoter I and IV in the burnout group, which also correlated with burnout symptoms. In addition, DNA methylation of promoter I had a significant negative effect on sBDNF. For DNA methylation of exon IX, we did not find a significant difference between the groups, nor associations with sBDNF. The Val66Met polymorphism neither differed between groups, nor was it associated with sBDNF levels. Finally, we did not observe differences in sBDNF level between the groups. Interestingly, we observed a significant negative association between depressive symptoms and sBDNF levels. The current study is the first to show that BDNF DNA methylation changes might play an important role in downregulation of the BDNF protein levels in burnout. The presence of depressive symptoms might have an additional impact on these changes.

Brain-Derived Neurotrophic Factor Modulates the Effect of Sex on the Descending Pain Modulatory System in Healthy Volunteers

Pain Medicine ◽  
2020 ◽  
Vol 21 (10) ◽  
pp. 2271-2279 ◽  
Author(s):  
Assunta Gasparin ◽  
Maxciel Zortea ◽  
Vinicius Souza dos Santos ◽  
Fabiana Carvalho ◽  
Iraci L S Torres ◽  
...  
Keyword(s):  
Sex Differences ◽  
Healthy Volunteers ◽  
Neurotrophic Factor ◽  
Pain Perception ◽  
Motor Evoked Potential ◽  
Brain Derived Neurotrophic Factor ◽  
Pain Modulation ◽  
Cross Sectional ◽  
Motor Pathway ◽  
Serum Bdnf

Abstract Objectives We investigated sex differences and the influence of brain-derived neurotrophic factor (BDNF) in the descending pain modulatory system (DPMS), as measured by change on the numerical pain scale (NPS; 0–10) during conditioned pain modulation (CPM task; primary outcome) and by function of the corticospinal motor pathway and heat pain thresholds (HPTs; secondary outcomes). Methods This cross-sectional study included healthy volunteers ranging in age from 18 to 45 years (32 male and 24 female). Assessment included serum BDNF, HPT, change on the NPS (0–10) during the CPM task, and motor-evoked potential (MEP) using transcranial magnetic stimulation (TMS). Results The MEP (Mv) amplitude was larger in male participants compared with female participants (mean [SE] = 1.55 [0.34] vs mean [SE] = 1.27 [0.27], respectively, P = 0.001). The mean NPS (0–10) during CPM task changed more substantially for female compared with male participants (mean [SE] = −3.25 [2.01] vs mean [SE] = −2.29 [1.34], respectively, P = 0.040). In addition, a higher serum BDNF (adjusted index for age) was associated with a larger decrease of the NPS during CPM task (P = 0.003), although further regression analyses by sex showed that this was only significant for females (P = 0.010). Conclusions Significant sex differences were identified in DPMS function and corticospinal motor pathway integrity. Nevertheless, BDNF was associated with the function of the DPMS in female but not male participants, indicating that sex and neuroplasticity state are crucial factors for pain perception in healthy subjects.

scholarly journals Peripheral Brain-Derived Neurotrophic Factor and Contactin-1 Levels in Patients with Attention-Deficit/Hyperactivity Disorder

2019 ◽  
Vol 8 (9) ◽  
pp. 1366 ◽  
Author(s):  
Liang-Jen Wang ◽  
Chih-Ching Wu ◽  
Min-Jing Lee ◽  
Miao-Chun Chou ◽  
Sheng-Yu Lee ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Attention Deficit ◽  
Neurotrophic Factor ◽  
Performance Test ◽  
Continuous Performance Test ◽  
Brain Derived Neurotrophic Factor ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Hyperactivity Disorder ◽  
Drug Naïve

Brain-derived neurotrophic factor (BDNF) facilitates neuronal growth and plasticity, and is crucial for learning and memory. Contactin-1 (CNTN1) is a member of the subfamily of neural immunoglobulin and is involved in the formation of axon connections in the developing nervous system. This cross-sectional study investigates whether BDNF and CNTN1 affect susceptibility to attention deficit/hyperactivity disorder (ADHD). A total of 136 drug-naïve patients with ADHD (108 boys and 28 girls) and 71 healthy controls (45 boys and 26 girls) were recruited. Blood samples were obtained to measure the plasma levels of BDNF and CNTN1 in each child. We found that BDNF levels in the ADHD boys exceeded those in the control boys, but BDNF levels in the ADHD girls were lower than those in the control girls. Boys who had higher BDNF levels performed worse on the Wechsler Intelligence Scale for Children—Fourth Edition, but girls who had higher BDNF levels made fewer omission errors in the Conners’ Continuous Performance Test. However, CNTN1 level did not differ significantly between patients and controls, and were not correlated to ADHD characteristics, regardless of gender. The findings suggest BDNF may influence sex-specific susceptibility to ADHD, but CNTN1 was not associated with ADHD pathophysiology.

scholarly journals Serum Brain-Derived Neurotrophic Factor Concentrations in Lean and Overweight Children and Adolescents

2006 ◽  
Vol 91 (9) ◽  
pp. 3548-3552 ◽  
Author(s):  
Areeg H. El-Gharbawy ◽  
Diane C. Adler-Wailes ◽  
Margaret C. Mirch ◽  
Kelly R. Theim ◽  
Lisa Ranzenhofer ◽  
...  
Keyword(s):  
Platelet Count ◽  
Children And Adolescents ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
High Energy ◽  
Analysis Of Covariance ◽  
Overweight Children ◽  
Convenience Sample ◽  
Pubertal Status ◽  
Serum Bdnf

Abstract Context: Brain-derived neurotrophic factor (BDNF) and its receptor appear to be important components of the leptin-signaling cascade involved in energy homeostasis, and mice with BDNF or TrkB gene haploinsufficiency have excessive adiposity. Little is known about the relationship between adiposity and BDNF, particularly in children. Objective: The objective of the study was to study the association of serum BDNF with measures of adiposity in children. Design/Setting/Patients: BDNF was determined by a sandwich-type ELISA after an overnight fast in convenience sample of 328 subjects, aged 3–19 yr enriched for extreme obesity. In 43, BDNF was also measured before, and again 1 h after, consuming a high-energy content (787 kcal) milkshake. Main Outcome Measures: Measures included associations between BDNF and measures of adiposity. Results: There were no significant univariate associations between log BDNF and adiposity measured by body mass index (BMI), BMI-Z score, or fat mass. However, in an analysis of covariance accounting for age, sex, race, pubertal status, and platelet count, BDNF was lower in overweight children (mean ± sd, 39.8 ± 24.8 vs. 47.0 ± 25.4 ng/dl, P = 0.03); in multiple regression analyses with log BDNF as the dependent variable, BMI (P = 0.03), BMI-Z (P = 0.01), and body fat (P < 0.02) were all negatively associated with BDNF once age, pubertal status, and platelet count were included in the model. Ingestion of a meal did not significantly alter serum BDNF 1 h later (P = 0.26). Conclusions: Serum BDNF is lower in extremely overweight children and adolescents than those of normal weight. It remains to be determined whether obese individuals with low serum BDNF for age and platelet count have mutations that alter BDNF function.

Evaluation of cytokines, oxidative stress markers and brain-derived neurotrophic factor in patients with fibromyalgia – A controlled cross-sectional study

Cytokine ◽  
2016 ◽  
Vol 84 ◽  
pp. 25-28 ◽  
Author(s):  
Aline Ranzolin ◽  
Angela Luzia Branco Pinto Duarte ◽  
Markus Bredemeier ◽  
Cláudio Antônio da Costa Neto ◽  
Bruna Maria Ascoli ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Cross Sectional Study ◽  
Oxidative Stress Markers ◽  
Sectional Study ◽  
Cross Sectional ◽  
Stress Markers

scholarly journals Brain-Derived Neurotrophic Factor Mitigates the Association Between Platelet Dysfunction and Cognitive Impairment

2021 ◽  
Vol 8 ◽  
Author(s):  
Jean-Christophe Bélanger ◽  
Véronique Bouchard ◽  
Jessica Le Blanc ◽  
Louisia Starnino ◽  
Mélanie Welman ◽  
...  
Keyword(s):  
Cognitive Function ◽  
Platelet Activation ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Cross Sectional Study ◽  
Cognitive Outcomes ◽  
Activity Levels ◽  
Platelet Activity ◽  
Cross Sectional ◽  
The Relationship

Background: Platelet hyperactivity is deleterious in coronary artery disease (CAD), requiring lifelong antiplatelet therapy, and is associated with worse cognitive outcomes. Upon activation, platelets release Brain-Derived Neurotrophic Factor (BDNF), a neurotrophin protective against cognitive decline. Given these apparently opposing effects of platelet activation on cognitive health, we investigated whether BDNF levels intercede in the relationship between platelet activation and cognitive function; and whether this relationship is moderated by the presence of CAD.Methods: In this cross-sectional study, 1,280 participants with (n = 673) and without CAD (n = 607) completed the Montreal Cognitive Assessment (MoCA). Plasma BDNF and soluble P-selectin (a marker of platelet activity) levels were assessed using multiplex flow cytometry.Results: In a mediation model, platelet activity was correlated with higher plasma BDNF concentrations (b = 0.53, p < 0.0001). The relationship between sP-selectin and BDNF concentrations was stronger for individuals without CAD (b = 0.71, p < 0.0001) than for CAD participants (b = 0.43, p < 0.0001; pinteraction <0.0001). Higher BDNF concentrations were associated with higher MoCA scores (b = 0.26, p = 0.03). The overall effect of platelet activity on cognitive performance was non-significant (total effect: b = −0.12, p = 0.13), and became significant when accounting for BDNF as a mediating factor (direct effect: b = −0.26, p = 0.01). This resulted in a positive indirect effect of platelet activity (via BDNF) on MoCA scores (b = 0.14, CI 95% 0.02–0.30), that was smaller in CAD participants than in non-CAD participants [Δ −0.07 (95% CI −0.14 to −0.01)].Conclusions: BDNF released from activated platelets could be a mitigating factor in a negative association between platelet activity and cognitive function.

Accelerometer-Measured, Habitual Physical Activity and Circulating Brain-Derived Neurotrophic Factor: A Cross-Sectional Study

2021 ◽  
pp. 1-10
Author(s):  
Nicole L. Spartano ◽  
Jayandra J. Himali ◽  
Ludovic Trinquart ◽  
Qiong Yang ◽  
Galit Weinstein ◽  
...  
Keyword(s):  
Physical Activity ◽  
Neurotrophic Factor ◽  
Smoking Status ◽  
Linear Trend ◽  
Brain Derived Neurotrophic Factor ◽  
Cross Sectional Study ◽  
Activity Levels ◽  
Vigorous Activity ◽  
Middle Aged ◽  
Cross Sectional

Background: One of the mechanisms suggested to link physical activity (PA) to favorable brain health is through stimulation of neural growth factors such as brain-derived neurotrophic factor (BDNF). Acute bouts of PA stimulate circulating BDNF levels. Objective: In this investigation, we assessed whether habitual, accelerometer-measured PA levels were related to circulating BDNF levels in a middle-aged cohort. Methods: In the Framingham Heart Study Third Generation cohort, 1,769 participants provided reliable accelerometry data and were not missing BDNF measurement and platelet counts. In a cross-sectional analysis, using multivariable regression, we related PA measures to serum BDNF levels, adjusting for age, sex, smoking status, platelet count, depression status, and accelerometer wear time. Results: Our study participants (mean age 47±9 years, 50.8% women) spent an average of 22.3 mins/day moderate-to-vigorous (MV)PA. Most PA variables (steps, MVPA, light activity, and sedentary time) were not related to BDNF levels (p > 0.05). We observed a non-linear trend, where 15–50 mins/week vigorous activity was associated with lower BDNF compared to those with 0 min vigorous activity (β= –0.049±0.024, p = 0.05), but with no significant associations at lower or higher vigorous activity levels. In smokers, MVPA was also associated with lower BDNF levels (β= –0.216±0.079, p = 0.01). Conclusion: Our study reveals that circulating BDNF is not chronically elevated in individuals with higher levels of habitual PA in middle-aged adults from the community and may even be chronically suppressed with higher PA in subgroups, including current smokers. These results do not contradict previous studies demonstrating that circulating BDNF rises acutely after PA.

scholarly journals Correlation between Serum Brain-Derived Neurotrophic Factor Level and Depression Severity in Psoriasis Vulgaris Patients

2019 ◽  
Vol 7 (4) ◽  
pp. 583-586 ◽  
Author(s):  
Muhammad Sjahrir ◽  
Irma Damayanti Roesyanto-Mahadi ◽  
Elmeida Effendy
Keyword(s):  
Negative Correlation ◽  
Neurotrophic Factor ◽  
Psoriasis Vulgaris ◽  
Severity Index ◽  
Brain Derived Neurotrophic Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Depression Severity ◽  
Bdnf Level ◽  
Cross Sectional ◽  
Serum Bdnf

BACKGROUND: Psoriasis vulgaris is a chronic inflammatory skin disorder that can lead to depression. There is a similarity in neurotrophic substance in the pathogenesis of psoriasis and depression; it’s called brain-derived neurotrophic factor (BDNF). BDNF level imbalance potentially affects the severity of psoriasis and depression. AIM: This study aims to know the correlation between serum BDNF level and depression severity in psoriasis vulgaris patient and also the correlation between serum BDNF level and psoriasis vulgaris severity. METHODS: This is an analytical cross-sectional study that 23 psoriasis vulgaris patients participated. All participants have performed serum BDNF level examination with enzyme-linked immunosorbent assay (ELISA). Depression severity assessed with Beck depression inventory-II (BDI-II) and psoriasis severity assessed with psoriasis area and severity index. Correlation between all variables was analysed with Spearman’s correlation test. RESULTS: Serum BDNF level and depression severity are a strongly negative correlation in psoriasis vulgaris patients (r = -0.667 with significant value p = 0.001). There is a moderate negative correlation between serum BDNF level with psoriasis vulgaris severity (r = -0.595 with significant value p = 0.003). CONCLUSION: In psoriasis vulgaris patients, a low level of serum BDNF may increase depression severity and psoriasis vulgaris severity.

Cognitive dysfunction and serum levels of brain-derived neurotrophic factor (BDNF) in primary anti-phospholipid syndrome (PAPS)

Rheumatology ◽  
2020 ◽  
Vol 60 (1) ◽  
pp. 179-187
Author(s):  
Renata F Rosa ◽  
Michelle Remião Ugolini-Lopes ◽  
Ana Paula Rossi Gandara ◽  
Margarete B G Vendramini ◽  
Kenia Repiso Campanholo ◽  
...  
Keyword(s):  
Cognitive Dysfunction ◽  
Neural Plasticity ◽  
Neurotrophic Factor ◽  
Univariate Analysis ◽  
Positive Association ◽  
Brain Derived Neurotrophic Factor ◽  
Screening Tests ◽  
Cross Sectional ◽  
Serum Bdnf ◽  
Anti Phospholipid Syndrome

Abstract Objectives Cognitive dysfunction (CD) is a poorly understood non-stroke central neurological manifestation in anti-phospholipid syndrome (APS). Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays an important role in neural plasticity and could potentially be a biomarker of CD in primary APS (PAPS). The aim of the study is to assess CD in PAPS patients and to evaluate its association with clinical data, anti-phospholipid antibodies and serum BDNF levels. Methods This cross-sectional study compared 44 PAPS patients and 20 healthy controls matched for age, gender and education. PAPS patients and controls underwent a standardized cognitive examination. The demographic, clinical and laboratory characteristics of patients were recorded. Serum BDNF was measured by Enzyme Linked Immunosorbent. Results Fourteen (31.8%) of the 44 patients with PAPS had CD compared with only one (5%) healthy control (P =0.019). PAPS patients presented lower serum BDNF levels when compared with controls (P =0.007). Lower levels of BDNF were associated with CD in PAPS patients (P =0.032). In the univariate analysis, a positive association was found between CD and livedo reticularis, deep vein thrombosis, stroke, seizure, smoking as well as a negative association with Mini Mental State Examination and serum BDNF. According to multivariate analysis, the only independent predictor of CD in PAPS was stroke (OR 137.06; 95% CI: 4.73, 3974.32; P =0.004). Conclusions CD is commonly reported in PAPS patients; however, its assessment lacks in standards and objective screening tests. The association between CD and low serum BDNF suggests that this neurotrophin can be a promising biomarker for PAPS cognitive impairment.

Sign in / Sign up

Export Citation Format

Share Document